Year of Publication

2021

College

Public Health

Date Available

5-5-2023

Degree Name

Master of Public Health (M.P.H.)

Committee Member

Deborah Erickson M.D.

Advisor

Mary Lacy Ph.D.

Co-Director of Graduate Studies

Erin Haynes Ph.D

Abstract

Purpose: Methenamine hippurate (MH) is a urinary antiseptic, indicated for prophylaxis of recurrent urinary tract infections (UTIs) but with only few and limited studies regarding its efficacy. To help address this knowledge gap we reviewed our experience with MH for UTI prophylaxis, focusing on women with recurrent uncomplicated UTIs.

Materials and Methods: The University of Kentucky electronic health record was queried to identify adults who were prescribed MH from the Urology clinic between January 2013 and January 2019. Charts were reviewed to assess patient-reported UTI frequency, demographics and relevant health factors. Treatment success was defined as 0-1 UTI in 6 months or 0-2 UTIs in 1 year.

Results: Of 670 patients prescribed MH, 508 did not meet inclusion criteria. The most common reasons for exclusion were complicated UTI, no return visit, treatment nonadherence and insufficient follow-up time. The primary study population was 162 women with recurrent uncomplicated UTIs: 41 age≥50. Success rates with MH were 83% and 77%, respectively. Success rates were not significantly associated with age, diabetes, immune suppression, high-tone pelvic floor dysfunction or (if postmenopausal) vaginal estrogen use. Exploratory study of patients using intermittent catheterization (n=30) or indwelling catheters (n=12) showed success in 67% and 50%, respectively.

Conclusions: MH had high success rates for women with recurrent uncomplicated UTIs. Patients using catheters had lower success rates. Prospective trials would strengthen the evidence to guide decisions for treatment and insurance coverage.

Download

Share

COinS